Coronavirus
Pfizer to consider vaccine sites outside US, Europe only after pandemic supply phase
Pfizer Inc will consider making its coronavirus vaccine outside the United States and Europe only after the “pandemic supply phase” is over, it said on Thursday, adding it was not currently talking to India over local production.
The comments came after Reuters reported on Wednesday, citing sources, that the US drugmaker had told the Indian government it wanted to produce the shot locally if assured of faster regulatory clearance and freedom on pricing and exports. The sources did not give a timeline.
For more coronavirus news, visit our dedicated page.
“At this time we are not in discussions for any additional local manufacturing for this vaccine,” said a spokeswoman for Pfizer, which has developed the vaccine with Germany’s BioNTech SE.
For all the latest headlines follow our Google News channel online or via the app.
“Once the pandemic supply phase is over and we enter a phase of regular supplies, Pfizer will certainly evaluate all additional opportunities available,” she told Reuters.
BioNTech’s chief executive told Bloomberg News this week the two companies could have the capacity to make 3 billion doses
next year, up from their plan to produce at least 2 billion doses this year.
India is the world’s largest vaccine maker, and its companies have deals to make the shots of Oxford University/AstraZeneca, Novavax Inc and Johnson & Johnson, besides several local ones.
Pfizer pulled an application last month seeking emergency approval for its product in India after the drug regulator declined its request to skip a small local safety trial. That has kept the vaccine out of one of the world’s biggest drug markets.
The company declined to comment when exactly it could again seek permission to sell in India, as promised during its withdrawal.
“We remain committed to working towards equitable and affordable access for our COVID-19 vaccine for people around the world including in India, and we welcome opportunities to collaborate with the government to fight COVID-19,” the spokeswoman said in an email.
Read more:
Coronavirus: India starts world’s largest COVID-19 vaccination drive
UK study shows single Pfizer vaccine dose reduces COVID-19 transmission
‘Real world’ study proves Pfizer vaccine 94 pct effective against COVID-19
Also Read
-
Pfizer could have capacity for 3 billion COVID-19 doses in 2022
BioNTech SE could have capacity to make 3 billion doses of Covid-19 vaccine with US partner Pfizer Inc. next year, the German company’s chief ... Coronavirus -
New Zealand’s PM says will buy enough Pfizer vaccines to inoculate entire population
New Zealand will buy additional COVID-19 vaccines, developed by Pfizer Inc and Germany’s BioNTech, which will be enough to vaccinate the whole country ... Coronavirus -
US scientists doubtful of one-shot regimen for Pfizer, Moderna COVID-19 vaccines: WSJ
U.S. scientists are skeptical of a one-shot regimen for Pfizer Inc and Moderna Inc COVID-19 vaccines, saying there isn't enough evidence that a single ... Coronavirus -
Fauci says US must stick to two-dose strategy for Pfizer, Moderna vaccines: Report
The United States must stick to a two-dose strategy for the Pfizer-BioNTech and Moderna COVID-19 vaccines, top US infectious disease official Anthony ... Coronavirus -
UK study shows single Pfizer vaccine dose reduces COVID-19 transmission
A single dose of the Pfizer COVID-19 vaccine developed in partnership with BioNTech could significantly reduce the risk of transmission after a single ... Coronavirus -
Pfizer studying effects of third COVID-19 vaccine dose
Pfizer announced Thursday that it has begun studying a third dose of its COVID-19 vaccine, part of a strategy to guard against mutated versions of the ... Coronavirus -
‘Real world’ study proves Pfizer vaccine 94 pct effective against COVID-19
The Pfizer Covid-19 vaccine has proven 94 percent effective in a study involving 1.2 million people in Israel, the first peer-reviewed real world ... Coronavirus
